Article
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
Clinical pharmacology and therapeutics - 1 Jul 2006
Le Meur Yannick, Djebli Nassim, Szelag Jean-Christophe, Hoizey Guillaume, Toupance Olivier, Rérolle Jean Philippe, Marquet Pierre
Abstract excerpt
BACKGROUND: The low and highly variable oral bioavailability of the immunosuppressant sirolimus is thought to result partly from genetic polymorphism of the CYP3A5 gene. METHODS: This study aimed to evaluate the contribution of the CYP3A5 single-nucleotide polymorphism A6986G to the interindividual variability of sirolimus pharmacokinetics in 47 renal transplant patients at steady state, 21 of whom were also...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.